2016 Epidemiological Survey of Dermatomycoses in Japan

Shimoyama, Harunari; Sei, Yoshihiro

doi:10.3314/mmj.19.007

Cited by 30 publications

(43 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the most common age group affected by P. aeruginosa interdigital infections was the 60-69 years group. This corresponds with the age of onset of tinea pedis [17]. Furthermore, other predisposing factors, such as scratching or rubbing, unreasonable treatment, and hot-water scalding are more common in this age group (data not shown).…”

Section: Discussionmentioning

confidence: 68%

Epidemiology of interdigital infections of toe web spaces in Shanghai, China: Etiology, risk factors, and therapeutic approaches

Yu¹,

Li²,

Kan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Interdigital infections are frequently misdiagnosed as tinea pedis and remain intractable to treatments because of high recurrence rates and potential complications. We aimed to understand the epidemiology of interdigital infections in Shanghai, China. Methods We conducted a cross-sectional study at Shanghai Dermatology Hospital from January 2019 to December 2019, enrolling 57 patients with acute interdigital inflammation. Patients received antibiotic therapy and underwent long-term follow-up. Clinical features and medical histories, including blood, bacterial, and mycologic examination results, cultures and drug susceptibility test results, and follow-up data were analyzed for pathogenic agents. Results We found Pseudomonas aeruginosa (40.35%), Staphylococcus aureus (36.84%), and other bacteria (22.8%). Compared to other bacteria, P. aeruginosa interdigital infection were more inclined to co-infect with fungal agents. Further, P. aeruginosa interdigital infections were frequently seen in the spring and autumn and in patients aged 60–69 years. However, interdigital infections caused by S. aureus occurred more frequently in the summer and in patients aged 31–40 years. We found that levofloxacin had excellent therapeutic effects. Conclusion Our findings may inform treatment and diagnostic guidelines and, subsequently, help reduce the rate of recurrence and improve patient outcomes following interdigital infections.

show abstract

Section: Discussionmentioning

confidence: 68%

Epidemiology of interdigital infections of toe web spaces in Shanghai, China: Etiology, risk factors, and therapeutic approaches

Yu¹,

Li²,

Kan³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In terms of age, the present study examined a wider range of patients compared with previously reported surveys [15]. Due to aging of the Japanese population, the proportion of patients aged > 80 years is increasing, which could pose problems in the future [17][18][19]. Therefore, we conducted a more-detailed age-speci c evaluation than previous studies.…”

Section: Discussionmentioning

confidence: 99%

Treatment Outcome With Fosravuconazole L-lysine Ethanolate (F-RVCZ) for Onychomycosis

Shimoyama

Sei

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Fosravuconazole L-lysine ethanolate (F-RVCZ), a ravuconazole prodrug, is a newly available agent with high expectations for efficacy in the treatment of onychomycosis. However, clinical data regarding the efficacy of F-RVCZ are limited because the drug was launched only in Japan in 2018. Therefore, we analyzed the outcome of F-RVCZ therapy in the treatment of onychomycosis at outpatient dermatology clinics in Japan. We examined data for 109 patients (68 male, 41 female) with varying clinical type, including total dystrophic onychomycosis and dermatophytoma, and a wide range of age groups, including the elderly. The complete cure rate at 12 weeks was 6.4% (7/109) and 67.9% (74/109) at the last visit (mean time to last visit: 32±14.2 weeks). Mean rate of improvement in the affected nail area was 49.1±23.3% at 12 weeks and 86.8±22.4% at the last visit. Efficacy at 12 weeks and the last visit, respectively, was as follows: none, 4 cases and 1 case; slight, 35 cases and 4 cases; moderate, 51 cases and 21 cases; significant, 12 cases and 9 cases; complete cure, 7 cases and 74 cases. There were no serious adverse events. This retrospective survey was the first large-scale analysis of actual clinical practice outcomes and had minimal exclusions. Compared to previous reports, our results demonstrated excellent efficacy of F-RVCZ therapy in a variety of patients. Considering our results and the ease of oral administration (1 capsule/day for 12 weeks) and few adverse events, F-RVCZ therapy appears to be a useful option for the treatment of onychomycosis.

show abstract

“…Onychomycosis caused by dermatophytes is found more frequently in the elderly than in younger patients. Patients in their 70s are the largest age population in Japan, accounting for 25.7% (420/1634) of cases according to a Japanese survey 7 . Age is the principal non‐modifiable risk factor for the development of onychomycosis.…”

Section: Discussionmentioning

confidence: 99%

Fosravuconazole to treat severe onychomycosis in the elderly

Noguchi

Matsumoto

Kimura

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Fosravuconazole is a novel oral antifungal drug developed in Japan and used to treat tinea unguium since 2018. Its excellent oral absorbability and systemic bioavailability has enabled short‐duration therapy of 3 months. Furthermore, no concomitant drugs are contraindicated due to the presence of the mild inhibitor of cytochrome P450 enzyme which is responsible for polypharmacy adverse effects. Therefore, it can be safely administrated to elderly patients. Elderly patients (≥65 years old) with severe onychomycosis (≥50% nail involvement) were treated with oral fosravuconazole 100 mg once daily for 12 weeks. The rate of involvement improved from 86.6% to 28.1% (P < 0.01). The efficacy (i.e. percentage of those rated as “improved” and better) and cure rate was 83.8% (31/37) and 29.7% (11/37), respectively. Furthermore, when focusing on the thin nail group (<3 mm), the efficacy and cure rate was 88.2% (15/17) and 58.8% (10/17), respectively. Although the serum γ‐glutamyltransferase levels increased in 21.6% (8/37), all patients recovered without any specific treatments.

show abstract

2016 Epidemiological Survey of Dermatomycoses in Japan

Cited by 30 publications

References 6 publications

Epidemiology of interdigital infections of toe web spaces in Shanghai, China: Etiology, risk factors, and therapeutic approaches

Epidemiology of interdigital infections of toe web spaces in Shanghai, China: Etiology, risk factors, and therapeutic approaches

Treatment Outcome With Fosravuconazole L-lysine Ethanolate (F-RVCZ) for Onychomycosis

Fosravuconazole to treat severe onychomycosis in the elderly

Contact Info

Product

Resources

About